VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NHrYWZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFTESoxKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF3NEOg{txO M3v1V3NCVkeHUh?=
human NCI-H720 cell NYrDNm1bT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{KwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTZ6MjFOwG0> M1T0eXNCVkeHUh?=
JVM-2 cell M{HrZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjYOXZbUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> NGK4XVlUSU6JRWK=
human NCI-H69 cell NYLPcIR1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6QTRzIN88US=> M3\JSXNCVkeHUh?=
human BV-173 cell NGjLWGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN M3\tZ3NCVkeHUh?=
human KU812 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn71TY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN NULmeFJnW0GQR1XS
human DU-145 cell NYLNR2k6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fvd2lvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPDV3NDFOwG0> MWfTRW5ITVJ?
KARPAS-45 cell NXfRZ2F4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHibnZ2UW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= M{Phd3NCVkeHUh?=
human AGS cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4n6RmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOVI2OSEQvF2= MmrKV2FPT0WU
human MOLT-13 cell M4LQSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnfrTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTl6MTFOwG0> MlvoV2FPT0WU
human NCI-H209 cell NY\qWWI6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTxTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTd3ODFOwG0> NUHvOFdOW0GQR1XS
human CTV-1 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1qz[mlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5Ozh7IN88US=> M1fiXXNCVkeHUh?=
LU-139 cell M2XBdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnJcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk1OzVizszN MVLTRW5ITVJ?
ML-2 cell Ml7PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7vUHJ5UW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjZ4MTFOwG0> MVvTRW5ITVJ?
human K5 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MkmxO{DPxE1? MlH4V2FPT0WU
human SBC-1 cell M2LVcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|YzKM7:TR?= NWHEV|FOW0GQR1XS
human COR-L88 cell NWDYcZp5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3rQRmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2ODFOwG0> M33hcHNCVkeHUh?=
human KY821 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;5TY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k3ODNizszN MomyV2FPT0WU
human HCC2218 cell Mk\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlrUTY5pcWKrdHnvckBw\iCqdX3hckBJS0N{MkG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTd{ODFOwG0> M33UZnNCVkeHUh?=
human ECC10 cell NHLoXI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M175VGlvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY2Ozh7IN88US=> Mm\wV2FPT0WU
human EW-3 cell M4\0bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHfTZ5hKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY3PjFzIN88US=> MmDPV2FPT0WU
human EW-18 cell MkWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnLzTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|Q3PzlizszN MXzTRW5ITVJ?
human UACC-257 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODN{NjFOwG0> MWXTRW5ITVJ?
human G-361 cell M2nMeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLTdpJKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41QTVzOTFOwG0> NVzOeplQW0GQR1XS
human HMV-II cell MkDpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnVN2JKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO M3XsZnNCVkeHUh?=
human DEL cell NUG5OVE5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkC3NFQh|ryP MX3TRW5ITVJ?
human IGROV-1 cell NVfJfpB4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fXRWlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDNzOEig{txO NF\ZdmtUSU6JRWK=
human SK-OV-3 cell NIGwSY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nJeWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjF4OUeg{txO M17BTnNCVkeHUh?=
human LAMA-84 cell M1m3W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjITY5pcWKrdHnvckBw\iCqdX3hckBNSU2DLUi0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44OTJ6NDFOwG0> M{fWZXNCVkeHUh?=
human NCI-H510A cell NW\MSpUyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nm[GlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? NHf3SI1USU6JRWK=
human CP66-MEL cell NUHwW49VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{\QTGlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? NEC5SnZUSU6JRWK=
human HAL-01 cell M3i4[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGhCVC1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlc6OThizszN NIjhWmZUSU6JRWK=
human RS4-11 cell  MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcxPTd|IN88US=> MoXxV2FPT0WU
human RPMI-8226 cell NVH1dI51T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{nyW2lvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56MkO3OkDPxE1? NY\Q[ndLW0GQR1XS
human NCI-H82 cell NH3SWYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3X2PWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDl|MEWg{txO NHnVe29USU6JRWK=
human NY cells NFnmdZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrrTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMke2N|ch|ryP MlTYV2FPT0WU
human MDA-MB-361 cell M3vEfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfCbodKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkSzNVU5KM7:TR?= NGXSN5VUSU6JRWK=
human MOLT-4 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPweINKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlzOUOg{txO NUG1RlM4W0GQR1XS
human DU-4475 cell M3;3UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA2PTZ3IN88US=> MY\TRW5ITVJ?
human ESS-1 cell NUe3SYxLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= MkDXV2FPT0WU
human NCI-H1299 cell M4DVUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LkN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? MVfTRW5ITVJ?
human COLO-684 cell MnLzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42QDF4NTFOwG0> NHjZdmhUSU6JRWK=
human MV-4-11 cell MkPQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlcyOTl7IN88US=> MWjTRW5ITVJ?
human D-542MG cell NXm2OlBJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXvRfXhRUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|OUK3NkDPxE1? NYL0VHBKW0GQR1XS
human A4-Fuk cell MkT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvQR3VMUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|Nk[yJO69VQ>? NYDzToZNW0GQR1XS
human HL-60 cell M3\xNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PFemlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlUzOjF{IN88US=> MXnTRW5ITVJ?
human NCI-H526 cell NE[2c2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QThyMTFOwG0> NET4SZlUSU6JRWK=
human L-363 cell M2C0PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\EVmlvcGmkaYTpc44hd2ZiaIXtZY4hVC1|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlc6OjV{IN88US=> M{D2dHNCVkeHUh?=
human A388 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjHTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64NFM5PCEQvF2= Mmr0V2FPT0WU
human MS-1 NVLlVZJJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjsTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64N|Q3PSEQvF2= MYXTRW5ITVJ?
human JAR cell NUTPcll6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4X3Z2lvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64OFkzOyEQvF2= NFjBTHBUSU6JRWK=
human TI-73 cell M3T5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\J[5JKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPjJ{IN88US=> MoTyV2FPT0WU
human CTB-1 cell MoL3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13NUmlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlE4QDJ3IN88US=> MXfTRW5ITVJ?
human SK-NEP-1 cell MonaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOzB|ODFOwG0> MYDTRW5ITVJ?
human HT-29 cell Mn3LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7QWY9KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTFzMTFOwG0> MYfTRW5ITVJ?
human NCI-H1092 cell M1TUS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;oTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC5|MUig{txO M4jsPHNCVkeHUh?=
human KMOE-2 cell M33JNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHq2bmVKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO MmjsV2FPT0WU
human EM-2 cell NVHMXphRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFQyKM7:TR?= M3PabnNCVkeHUh?=
human RT-112 cell M1Swfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlM6QDRizszN M1n6enNCVkeHUh?=
human DB cell M4rR[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1? MkW0V2FPT0WU
human NCI-H1770 cell MnvNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7ibJR1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= MX7TRW5ITVJ?
human CAL-54 cell MnP1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PNb2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzNizszN NW\XO4FDW0GQR1XS
human NB14 cell Mnm2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{mxcWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlY{QTVizszN MnO1V2FPT0WU
human RPMI-7951 cell M1LWc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfsUHpKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP MoX5V2FPT0WU
human T47D cell NGO0UHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;UT|lKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zOjR|IN88US=> NHvqPGRUSU6JRWK=
human A549 cell Mo\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnsVpVKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=> MYDTRW5ITVJ?
human A2780 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGHOTXRKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> NV\RWFh{W0GQR1XS
human SK-MEL-24 cell M2TaRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFrKOJNKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN|LkCzNVEh|ryP NYfrOoprW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID